Benzinga·Mar 17·Vandana SinghImmunityBio Surges on NCCN Bladder Cancer Guideline Inclusion for AnktivaImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway. IBRXbladder cancerAnktiva
GlobeNewswire Inc.·Mar 9·Castle Biosciences, Inc.Castle Biosciences' Melanoma Test Validates Risk Stratification in Landmark 912-Patient StudyCastle Biosciences' DecisionDx-Melanoma test confirmed 2.6% nodal positivity in 912 patients predicted low-risk, supporting safe SLNB avoidance and validating the diagnostic platform. CSTLgene expression profileprecision oncology